Clinical Trial

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

Study acronym: OCTOPOD-IP
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2027-12 -> 2027-09 2026-04-23
minor Completion moved earlier: 2027-12 -> 2027-09 2026-04-23
Trial Details
NCT Number NCT07211659
Lead Sponsor Theolytics Limited
Conditions Ovarian Cancer
Enrollment 18 participants
Start Date 2026-02-13
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-22